A study linked high expression of the protein desmoglein-2 (DSG2) to lower survival in people with myeloma. Data suggest that high DSG2 expression is…
News
A combination treatment using two Johnson & Johnson immunotherapies outperformed standard care regimens in reducing the risk of disease progression and death among people…
The experimental anticancer therapy CR-001 was generally well tolerated in a first-in-human clinical trial that tested several doses in 11 people with acute myeloid leukemia…
Maintenance therapy for myeloma can be stopped after two years without raising the risk of disease progression or death, a new study shows. “For…
An anticancer vaccine targeting a common genetic driver of pancreatic cancer was shown to be safe in an early clinical trial, with the results…
Dosing has begun in a Phase 3 clinical trial testing whether the antibody therapy Gamunex-C (immune globulin injection [human], 10% caprylate/chromatography purified) can help prevent…
Combining immunotherapy with an experimental cell therapy from Ernexa Therapeutics completely eliminated ovarian cancer in two-thirds of mice in laboratory experiments. The new data,…
The U.S. Food and Drug Administration (FDA) has set a date for next year by which it will decide whether or not to approve a…
July 15 marks the eighth annual Glioblastoma Awareness Day in the U.S., and advocates are calling for continued efforts to advance research and improve life…
The U.S. Food and Drug Administration (FDA) has approved a new version of Sarclisa (isatuximab), an approved treatment for multiple myeloma sold by…
